Clinical improvements were achieved and maintained for up to 3 years among bDMARD-naïve patients with PsA who received bimekizumab.

Belgian drugmaker UCB (Euronext: UCB) today announced new three-year data from Phase III trials, and their open-label ...

Women with axial spondyloarthritis are less likely than men to respond to multiple different classes of advanced therapies, ...

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

NDORMS researchers have identified a primary source of inflammatory IL-17 driving spondyloarthritis, paving the way for the ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.

Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful ...

A salty snack may seem harmless, but scientists are learning it can do more than raise your blood pressure. It might also affect your mental health. A new study has found that too much salt in the ...

“Bimekizumab is launching extremely well as IL-17A/F has emerged as superior to IL-17A inhibition in several important indications. Uniquely, we could have the best targeting approaches for both ...

With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, ...

The Bonn research findings provide clues as to how these immune cells could contribute to the development of cancer: they produce a Neurotransmitter called interleukin-17A (IL-17A). "This ...